CDKN3 Antibody

1. Results demonstrate that upregulation of p27 is involved in the knockdown of CDKN3-induced decrease in cell proliferation, increase in cell cycle arrest and apoptosis, decrease in invasion, and increase in radiosensitivity. PMID: 28109073
2. the mechanism of CDKN3 overexpression in human cancer PMID: 28504190
3. CDKN3 is frequently upregulated in gastric cancer tissues and cell lines and is related to advanced clinical stage, recurrence, and poor clinical outcome in gastric cancer. The functional data strongly suggest that CDKN3 behaves as an oncogene in gastric cancer, and downregulation of CDKN3 could inhibit gastric cancer cell proliferation, migration, and invasion, and induce cell cycle arrest and apoptosis. PMID: 27983933
4. CDKN3 may act as a tumor suppressor in liver tissues by modulation of the cell survival signal transduction, monitoring carcinogenesis and elimination of abnormal cells. PMID: 27314282
5. These results suggest that CDKN3 acts as an oncogene during breast cancer progression. The in vitro silencing of CDKN3 promoted apoptosis, induced G1 phase cell cycle arrest and inhibited cell migration. PMID: 27314680
6. Knockdown of Cdkn3 stabilizes Mps1 at centrosomes. PMID: 26586430
7. CDKN3 mRNA may be a good survival biomarker and potential therapeutic target in cervical cancer PMID: 26372210
8. CDKN3 overexpression in lung adenocarcinoma is not attributed to alternative splicing or mutation but is likely due to increased mitotic activity, arguing against CDKN3 as a tumour suppressor PMID: 26554648
9. CDKN3 knockdown reduces cell proliferation, invasion and promotes apoptosis in human ovarian cancer cells. PMID: 26191143
10. These results highlight the importance of CDKN3 in Bcr-Abl-mediated leukemogenesis. PMID: 25360622
11. High CDKN3 expression is associated with colorectal cancer. PMID: 25735390
12. these data identify KAP as a major regulator of cell division via interactions with numerous target proteins. aberrant splicing or miR-26a decreases KAP expression to promote glioblastoma growth and invasion. PMID: 24704824
13. CDKN3 may play an important role in the development and proliferation of epithelial ovarian cancer PMID: 24573179
14. KAP is overexpressed in alcohol-related hepatocellular carcinoma. PMID: 23292002
15. RelB activation is key for promoting multiple myeloma cell survival through the upregulation of anti-apoptotic proteins, in particular, CIAP2. PMID: 23555623
16. CDKN3 controls mitosis through the CDC2 signaling axis. PMID: 23775190
17. High CDKN3 expression is associated with cervical cancer. PMID: 23405241
18. cyclin-dependent kinase-associated protein phosphatase expression was associated with poorly differentiated Renal cell carcinoma PMID: 21396835
19. These results suggest that CDKN3 acts as an oncogene in human hepatocellular carcinoma and antagonism of CDKN3 may be of interest for the treatment of HCC. PMID: 22390936
20. analysis of CDKN3 cell cycle networks and the molecular mechanism of non-malignancy associated hepatitis/cirrhosis and HCC transformation PMID: 21535270
21. Identification of a KAP domain that interacts with cyclin-dependent kinase 2. PMID: 12745075
22. In choline-deficient neuroblastoma cells, the promoter of the cyclin-dependent kinase inhibitor 3 gene (CDKN3) was hypomethylated. This was associated with increased expression of CDKN3 gene product kinase-associated phosphatase (KAP) PMID: 15147518
23. Pax3 represses transcription through a novel mechanism involving competition between corepressor KAP1 and the heterochromatin-binding protein HP1gamma PMID: 16945326
24. the reduction of KAP1 levels promotes p53-dependent p21 induction and inhibits cell proliferation in actinomycin D-treated cells. PMID: 17056014

Show More

Hide All

HGNC: 1791

OMIM: 114550

KEGG: hsa:1033

STRING: 9606.ENSP00000335357

UniGene: Hs.84113